Uncommon Cents Investing LLC Sells 627 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Uncommon Cents Investing LLC reduced its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 20,753 shares of the medical equipment provider’s stock after selling 627 shares during the quarter. Uncommon Cents Investing LLC’s holdings in Zimmer Biomet were worth $2,192,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ZBH. Romano Brothers AND Company increased its holdings in shares of Zimmer Biomet by 1.1% in the fourth quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after purchasing an additional 102 shares during the last quarter. HB Wealth Management LLC boosted its holdings in shares of Zimmer Biomet by 5.9% during the 4th quarter. HB Wealth Management LLC now owns 4,302 shares of the medical equipment provider’s stock worth $455,000 after buying an additional 241 shares during the period. Wedge Capital Management L L P NC grew its stake in Zimmer Biomet by 1.6% in the 4th quarter. Wedge Capital Management L L P NC now owns 105,920 shares of the medical equipment provider’s stock valued at $11,188,000 after buying an additional 1,688 shares during the last quarter. Boston Common Asset Management LLC lifted its position in Zimmer Biomet by 1.1% during the fourth quarter. Boston Common Asset Management LLC now owns 49,752 shares of the medical equipment provider’s stock worth $5,255,000 after acquiring an additional 528 shares during the last quarter. Finally, Border to Coast Pensions Partnership Ltd boosted its holdings in shares of Zimmer Biomet by 90.4% during the fourth quarter. Border to Coast Pensions Partnership Ltd now owns 295,605 shares of the medical equipment provider’s stock worth $31,204,000 after acquiring an additional 140,351 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on ZBH shares. Oppenheimer dropped their price target on Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a report on Tuesday, October 15th. Evercore ISI dropped their target price on Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Barclays decreased their price target on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Raymond James dropped their price objective on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating for the company in a research note on Monday, October 14th. Finally, Royal Bank of Canada increased their target price on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research report on Monday, November 4th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $123.33.

Zimmer Biomet Trading Up 0.7 %

Shares of Zimmer Biomet stock opened at $109.65 on Monday. The firm has a market capitalization of $21.83 billion, a PE ratio of 20.85, a price-to-earnings-growth ratio of 1.79 and a beta of 1.02. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The firm’s 50 day moving average is $107.84 and its 200 day moving average is $108.01. Zimmer Biomet Holdings, Inc. has a 1 year low of $100.67 and a 1 year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion during the quarter, compared to the consensus estimate of $1.80 billion. During the same period in the prior year, the business earned $1.65 earnings per share. The company’s revenue for the quarter was up 4.1% compared to the same quarter last year. Equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Monday, December 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s payout ratio is 18.25%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.